We are pleased to announce the introduction of a new Birmingham Quality pilot EQA programme for immunosuppressants starting in December 2016.

The following analytes (and approximate coverage) will be included in the programme which will run with a monthly frequency and will comprise 3 specimens per distribution. Not all analytes will be presented in the same tube.

We understand that in order to accurately reflect laboratory practices, EQA specimens should be in the same matrix as patient samples wherever possible. For this reason, we will be providing whole blood samples for Ciclosporin, Tacrolimus, Sirolimus and Everolimus analysis; Mycophenolate will be a serum sample as per standard laboratory practice.

Scheme Particulars Indicative Details
Number of distributions per year (nominal) 12
Specimens per distribution 3
Frequency of distribution Monthly
Material distributed Whole blood (except mycophenolate which is in Serum)
Sample volume (mL) 0.9 (per analyte)
Programme Director(s) / Organiser(s) Jane French (acting)

This scheme is currently not accredited.

Analyte Approximate Range Default Scheme Units
Ciclosporin 0 – 2000 µg/L
Tacrolimus 0 – 30 µg/L
Sirolimus 0 – 30 µg/L
Everolimus 0 – 30 µg/L
Mycophenolate 0 – 15 mg/L

We intend the scheme to be ‘pick and mix’, whereby you can register for as many or as few analytes as you require. Detailed pricing information outlining the fees that will be charged for the programme from April 2017 onwards, will be supplied early in the New Year.

Please use the sign up form to register your interest in this scheme (quoting your UK NEQAS Laboratory ID where available). We would encourage you to provide us with details of which analytes you measure and the analyser and ‘kit’ (reagent and calibrator) you are using. This will help us tailor the scheme to your needs.

  • Download current UK charges list 129 KB
  • Download current Europe charges list 128 KB
  • Download current Overseas charges list 130 KB
  • Download Immunosuppressants Pilot 2017 schedule 42 KB

Last Updated: